L’Oréal has voluntarily recalled all lots of its acne treatment, Effaclar Duo, in the U.S. due to concerns that the product may be contaminated with benzene, a known carcinogen. Effaclar
Research has shown that individuals with darker Fitzpatrick skin types (III-VI) face a higher risk of developing post-inflammatory hyperpigmentation (PIH). According to studies, this increased susceptibility is due to larger
Alphyn has announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin Hydrogel, a groundbreaking treatment for mild-to-moderate atopic dermatitis (AD).
A potential new treatment for bullous pemphigoid (BP) is on the horizon as the U.S. Food and Drug Administration (FDA) grants priority review to Dupixent’s (dupilumab) supplemental biologics license application
Galderma recently announced the results of its clinical trial exploring the benefits of combining Restylane® Lyft™ or Contour™ with Sculptra® in patients experiencing facial volume loss due to medication-driven weight
DELTA TEEN is a phase 3 clinical trial by LEO Pharma that evaluated Anzupgo® (delgocitinib) 20mg/g cream for adolescents with moderate-to-severe chronic hand eczema (CHE). The trial demonstrated positive results
During a recent phase 2 study, researchers revealed that a combination of baricitinib and narrowband UV-B therapy significantly improved both disease activity and quality of life for individuals living with
Fesarius Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its DermiSphere Hydrogel Dermal Regeneration Template (DermiSphere hDRT). This innovative product represents
Although cosmetic treatments have traditionally been geared more towards the adult population, current data reveals a growing trend in cosmetic procedures among pediatric patients. This study aimed to explore the
Research conducted over the years has led to the discovery of the axolotl salamanders (Ambystoma mexicanum) and their remarkable regenerative abilities. These findings offer promising insights for regenerative medicine, skin
In a recent press release, Bristol Myers Squibb announced the positive results of their pivotal Phase 3 trials (POETYK PsA-1 and POETYK PsA-2) evaluating the safety and efficacy of Sotyktu
A recent Medscape report revealed that 24% of respondents use AI tools to analyze medical literature and data. While these AI tools can help organize data and generate content, they
Organon has announced the recent approval of Vtama ® (tapinarof) cream 1% for atopic dermatitis (AD) in adults and children aged 2 years and older. Vtama, an aryl hydrocarbon receptor agonist,
Diet, which plays a critical role in reducing inflammation and improving quality of life, has emerged as a significant factor in managing inflammatory diseases. Concerns, however, continue to mount over
A recent study published in the Journal of Drugs in Dermatology evaluated the safety and efficacy of a novel device combining monopolar radiofrequency (RF) and high-intensity facial electrical stimulation (HIFES)
UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. This approval is significant
A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen, called Essential Six (RATIONALE), includes
A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from the Explorys databases, the study
The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news brings hope to the EB
A recent study published in the Journal of the American Medical Association (JAMA Dermatology) found that patients with newly diagnosed alopecia areata (AA) have a higher prevalence and incidence of
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
